MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
iRhythm Technologies Cost of Revenue 2011-2026 | IRTC
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue iRhythm Technologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184 M | 161 M | 129 M | 109 M | 70.3 M | 52.5 M | 38.8 M | 28.2 M | 20.9 M | 14.7 M | 10.6 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | 10.6 M | 74.5 M |
Quarterly Cost of Revenue iRhythm Technologies
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.8 M | 49.5 M | - | 46.1 M | 44.6 M | 44.4 M | - | 42.1 M | 37.9 M | 35.8 M | - | 33 M | 31.8 M | 30.6 M | - | 29.3 M | 26 M | 23.5 M | - | 18.2 M | 15.5 M | 16.1 M | - | 13.8 M | 13 M | 11.8 M | - | 38.8 M | 9.49 M | 8.55 M | - | 6.92 M | 6.74 M | 6.34 M | - | 5.28 M | 5.16 M | 4.66 M | - | 3.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53.8 M | 3.75 M | 23.7 M |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
6.65 B | $ 19.29 | 0.94 % | $ 9.84 B | USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 193.47 | -0.31 % | $ 55.7 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
8.41 M | $ 8.47 | -1.99 % | $ 171 M | USA |
 |
Harvard Bioscience
HBIO
|
46.2 M | $ 0.65 | -2.78 % | $ 27.6 M | USA |
 |
Repro Med Systems
KRMD
|
11.8 M | $ 5.87 | 1.03 % | $ 268 M | USA |
 |
Alcon
ALC
|
3.58 B | $ 77.77 | -1.32 % | $ 40.4 B |  Schweiz |
 |
Nephros
NEPH
|
5.83 M | $ 4.85 | -0.62 % | $ 50.4 M | USA |
 |
AtriCure
ATRC
|
118 M | $ 39.03 | -1.33 % | $ 1.83 B | USA |
 |
ICU Medical
ICUI
|
1.56 B | $ 140.96 | -1.2 % | $ 3.44 B | USA |
 |
electroCore
ECOR
|
2.8 M | $ 4.58 | 2.02 % | $ 25.3 K | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 12.67 | -1.32 % | $ 518 M | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 81.0 | -1.17 % | $ 16.1 B | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 111.82 | -0.97 % | $ 5.42 B | USA |
 |
LeMaitre Vascular
LMAT
|
69 M | $ 80.16 | -1.16 % | $ 1.8 B | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 79.41 | -0.92 % | $ 4 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 8.7 | -3.01 % | $ 180 M | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 129.0 | -0.82 % | $ 6.88 B | USA |
 |
STERIS plc
STE
|
3.06 B | $ 248.38 | -2.03 % | $ 24.5 B | USA |
 |
Merit Medical Systems
MMSI
|
713 M | $ 86.87 | -1.44 % | $ 5.06 B | USA |
 |
Intuitive Surgical
ISRG
|
2.72 B | $ 560.97 | -0.95 % | $ 199 B | USA |
 |
OraSure Technologies
OSUR
|
106 M | $ 2.44 | 0.83 % | $ 182 M | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.01 | 0.5 % | $ 20.5 M |  Israel |
 |
Utah Medical Products
UTMD
|
20.2 M | $ 55.92 | -0.08 % | $ 203 M | USA |
 |
Milestone Scientific
MLSS
|
2.2 M | $ 0.28 | 3.55 % | $ 22.3 M | USA |
 |
Stereotaxis
STXS
|
11.9 M | $ 2.3 | - | $ 186 M | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.14 B | $ 21.63 | -0.37 % | $ 3.72 B | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 37.98 | -1.3 % | $ 125 M | USA |
 |
Predictive Oncology
POAI
|
826 K | - | - | $ 32.4 M | USA |
 |
Pulse Biosciences
PLSE
|
11.9 M | $ 13.67 | -0.47 % | $ 657 M | USA |
 |
ResMed
RMD
|
1.55 B | $ 242.63 | 0.73 % | $ 35.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.32 | -0.96 % | $ 2.3 B | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 164.05 | 0.11 % | $ 9.14 M | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 23.92 | -1.08 % | $ 1.1 B | USA |
 |
Retractable Technologies
RVP
|
34.1 M | $ 0.77 | 0.16 % | $ 23.1 M | USA |
 |
STAAR Surgical Company
STAA
|
74.3 M | $ 23.32 | 1.0 % | $ 1.15 B | USA |
 |
Teleflex Incorporated
TFX
|
1.34 B | $ 121.83 | -0.17 % | $ 5.71 B | USA |
 |
West Pharmaceutical Services
WST
|
1.89 B | $ 272.37 | -1.04 % | $ 19.9 B | USA |